×
ADVERTISEMENT

Biosimilar

FDA Approves First Interchangeable Omalizumab Biosimilar

The FDA announced it has approved a biosimilar version of omalizumab. The drug, which will be marketed as Omlyclo ...

MARCH 7, 2025

FDA Approves Pyzchiva Biosimilar to Stelara

Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...

JULY 3, 2024

Biosimilar Adoption Grows, but Challenges Remain for Adoption

A new survey from Vizient sheds light on the state of biosimilar adoption in the United States ahead of the ...

SEPTEMBER 13, 2022

Third Biosimilar to Bevacizumab Approved

The FDA approved bevacizumab-maly (Alymsys, Amneal Pharmaceuticals), a biosimilar to bevacizumab (Avastin, ...

APRIL 19, 2022

Navigating the Complexities Of Biosimilar Use in Pediatrics

When switching from an originator biologic to a biosimilar for pediatric patients, making the choice can be ...

APRIL 11, 2022

The Case for Switching to Rituximab Biosimilar

Switching from originator rituximab (Rituxan, Genentech) to rituximab-abbs (Truxima, Teva) can save an institution ...

FEBRUARY 8, 2022

New Survey Finds Biosimilars Have Wide Acceptance

Nearly two-thirds of managed care stakeholders polled in a recent survey said they are covering some biosimilar ...

JANUARY 27, 2022

Biosimilar Switches Work At Large and Small Centers

Large health systems as well as small community hospitals can successfully convert to oncology biosimilars and ...

MARCH 4, 2021

Overcoming Biosimilar Hesitancy

Biosimilars have the potential to significantly reduce costs for medical centers, but the adoption rate is still ...

JANUARY 20, 2021

FDA Approves Riabni, Third Biosimilar to Rituxan

The FDA Approved Amgen's Riabni, the 3rd biosimilar to the originator, U.S.-licensed Rituxan.

DECEMBER 18, 2020

Feds to Push for More Biosimilar Competition

The FDA and the Federal Trade Commission (FTC) announced they will take further action to stem anticompetitive ...

MARCH 12, 2020

FDA Approves Abrilada, Biosimilar to Humira

This approval marks the 25th biosimilar approved in the United States, but only a handful are currently available. ...

NOVEMBER 19, 2019

Load more